[Ip-health] 2 AMR job vacancies at GARD
jarkinstall at dndi.org
Thu Jul 21 04:00:57 PDT 2016
In May 2016, WHO and the Drugs for Neglected Diseases initiative launched the Global Antibiotic Research and Development Partnership, a not for profit research and development organization to develop new antibiotic treatments addressing antimicrobial resistance and to promote their responsible use for optimal conservation, while ensuring equitable access for all. Two positions have opened up to lead on the key start-up projects that GARD is currently preparing for launch by the end of the year.
Senior Project Manager, Antibiotic Memory Recovery initiative (AMRi)
AMRi aims to identify, compile, and openly share know-how, information and assets from existing resources - human, electronic, and material - within an open access platform in order to stimulate and enhance the antibiotic drug discovery and development ecosystem at large by:
* Identifying researchers and drug developers active, or that were active in the field of antibiotic R&D that hold specific memory of forgotten, withdrawn, or abandoned antibiotics, and establishing a publicly available, online database.
* Recovering and archiving published (including patent searches) and whenever possible unpublished data from forgotten, withdrawn, or abandoned antibiotics, including in priority pharmaceutical companies' stalled projects, or compounds shelved due to mergers or closures.
* Identifying and ultimately bringing together relevant molecule collections (structures, materials, compounds, and reagents) which could potentially be resynthesized where necessary and shared in an 'antibiotic memory box' to research groups, along data, key individuals involved, and any new information generated by others in an open source manner
* Evaluate and scope for specific collaborations with relevant entities in order to accelerate R&D of the most relevant AMRi compounds according to GARD's mandate
Neonatal Sepsis (NeoAMR) Project Leader
NeoAMR aims to develop new, globally applicable, empiric antibiotic regimens and strategies for the treatment of neonatal sepsis in settings with varying prevalence of MDR pathogens through the following objectives:
* Design and conduct pharmacokinetic, observational and interventional studies in high MDR setting to determine efficacy and safety of new empiric regimens compared to existing therapies
* Develop a global network of neonatal infection centres/experts to design and conduct studies on optimal management of off patent antibiotics & other interventions in neonatal sepsis with MDR pathogens
* Determine a method for appropriate use of empiric antibiotic regimens for the management of neonatal sepsis in settings with varying prevalence of MDR pathogens.
Deadline for applications for both positions is 31 July. Please do circulate to interested parties,
Thanks in advance.
James Arkinstall | Head of Communications and Advocacy
Drugs for Neglected Diseases initiative
15 Chemin Louis-Dunant | 1202 Geneva | Switzerland
Tel: +41 22 9077 885 | Mob: +41 79 3929 823 jarkinstall at dndi.org<mailto:jarkinstall at dndi.org> | skype: dndi-james-arkinstall
Best Science for the Most Neglected | www.dndi.org<http://www.dndi.org/>
More information about the Ip-health